We interviewed live Nick Kadysh, CEO of PharmAla Biotech Inc. (MDMA.CSE) on LinkedIn Live. We discussed the challenges and innovations behind developing scalable, compliant processes for the supply of LaNeo™ MDMA and other novel MDXX compounds — and what this means for the future of psychedelic-assisted therapy. Take an inside look at how PharmAla is shaping the next generation of clinical-grade entactogens.